Cargando…

High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas

BACKGROUND: Immunotherapy has demonstrated encouraging clinical benefits in patients with advanced breast carcinomas and Programmed death ligand 1 (PD-L1) expression has been proposed as an immunotherapy biomarker. Challenges with current PD-L1 testing exist and tumor mutation burden (TMB) is emergi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mei, Ping, Freitag, C. Eric, Wei, Lai, Zhang, Yunxiang, Parwani, Anil V., Li, Zaibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212599/ https://www.ncbi.nlm.nih.gov/pubmed/32393302 http://dx.doi.org/10.1186/s13000-020-00971-7

Ejemplares similares

Prognostic analysis of patients with breast cancer based on tumor mutational burden and DNA damage repair genes
por: Teng, Xu, et al.
Publicado: (2023)

DNA Damage Repair Gene Set as a Potential Biomarker for Stratifying Patients with High Tumor Mutational Burden
por: Chiu, To-Yuan, et al.
Publicado: (2021)

Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma
por: Wu, Dongping, et al.
Publicado: (2022)

DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients
por: Gu, Weiguang, et al.
Publicado: (2023)

DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden
por: Hsiehchen, David, et al.
Publicado: (2020)

DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer
por: Dai, Jiawei, et al.
Publicado: (2021)

Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing
por: Wang, Hai-Yun, et al.
Publicado: (2021)

Mutational signatures are jointly shaped by DNA damage and repair
por: Volkova, Nadezda V., et al.
Publicado: (2020)

Analysis of mutations in DNA damage repair pathway gene in Chinese patients with hepatocellular carcinoma
por: Li, Jiarong, et al.
Publicado: (2022)

Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer
por: Xiao, Weikai, et al.
Publicado: (2021)

Mutational spectra and mutational signatures: Insights into cancer aetiology and mechanisms of DNA damage and repair
por: Phillips, David H.
Publicado: (2018)

High Tumor Mutation Burden and DNA Repair Gene Mutations are Associated with Primary Resistance to Crizotinib in ALK-Rearranged Lung Cancer
por: Xiao, Dakai, et al.
Publicado: (2021)

Oxidative DNA Damage and Repair: Mechanisms, Mutations, and Relation to Diseases
por: Roginskaya, Marina, et al.
Publicado: (2023)

DNA damage repair mutations in pancreatic cancer– prognostic or predictive?
por: Hu, Ya-Fei, et al.
Publicado: (2023)

BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma
por: Herbert, Katharine, et al.
Publicado: (2019)

Mutational spectrum of DNA damage and mismatch repair genes in prostate cancer
por: Bugoye, Fidelis Charles, et al.
Publicado: (2023)

Genomic alterations associated with mutational signatures, DNA damage repair and chromatin remodeling pathways in cervical carcinoma
por: Halle, Mari K., et al.
Publicado: (2021)

Comprehensive Study of Telecytology Using Robotic Digital Microscope and Single Z-Stack Digital Scan for Fine-Needle Aspiration-Rapid On-Site Evaluation
por: Yao, Keluo, et al.
Publicado: (2018)

Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
por: Labriola, Matthew Kyle, et al.
Publicado: (2020)

Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma
por: Wong, Mary, et al.
Publicado: (2021)

Genomic Alterations and Tumor Mutation Burden in Merkel Cell Carcinoma
por: Brazel, Danielle, et al.
Publicado: (2023)

PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer
por: Zhang, Min, et al.
Publicado: (2020)

MDN1 Mutation Is Associated With High Tumor Mutation Burden and Unfavorable Prognosis in Breast Cancer
por: Hao, Shuai, et al.
Publicado: (2022)

Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma
por: Chae, Young Kwang, et al.
Publicado: (2019)

Tumor mutation burden: from comprehensive mutational screening to the clinic
por: Galuppini, Francesca, et al.
Publicado: (2019)

Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
por: Thomas, Alexandra, et al.
Publicado: (2018)

Tumor mutational burden as a predictor of immunotherapy response in breast cancer
por: O’Meara, Tess A., et al.
Publicado: (2021)

Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2023)

The effects of altered DNA damage repair genes on mutational processes and immune cell infiltration in esophageal squamous cell carcinoma
por: Yuan, Huangbo, et al.
Publicado: (2023)

Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma
por: Xie, Xiaona, et al.
Publicado: (2021)

Tumor mutational burden and immune signatures interplay in renal cell carcinoma
por: Yakirevich, Evgeny, et al.
Publicado: (2020)

Integrated Analysis of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma
por: Zhao, Yulan, et al.
Publicado: (2022)

Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma
por: Franses, Joseph W, et al.
Publicado: (2022)

Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma
por: Gabbia, Daniela, et al.
Publicado: (2023)

DNA Repair and Replication-Related Gene Signature Based on Tumor Mutation Burden Reveals Prognostic and Immunotherapy Response in Gastric Cancer
por: Zhang, Lei, et al.
Publicado: (2022)

FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer
por: Guo, Zixin, et al.
Publicado: (2021)

Tumor mutation burden associated with miRNA-gene interaction outcome mediates the survival of patients with liver hepatocellular carcinoma
por: Yu, Qing-Jiang, et al.
Publicado: (2020)

Racial disparities in patient survival and tumor mutation burden, and the association between tumor mutation burden and cancer incidence rate
por: Zhang, Wensheng, et al.
Publicado: (2017)

LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma
por: Yu, Ge, et al.
Publicado: (2022)

DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes
por: Vidotto, Thiago, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5lbetfkflobklgnhai287osdk3